6-ketodiosgenin

6-Ketodiosgenin: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Nomenclature

6-Ketodiosgenin (also written as 6-Keto Diosgenin or 6-keto-diosgenin) is a semi-synthetic or oxidatively modified derivative of diosgenin, a naturally occurring steroidal sapogenin. 6-Keto Diosgenin is a derivative of diosgenin, a naturally occurring steroidal sapogenin. The compound is named for its most defining structural feature: in the context of 6-Keto Diosgenin, the molecule features a ketone group at the 6-position, which alters its binding affinity and metabolic fate.

The parent molecule, diosgenin itself, is extensively characterized in the chemical literature. Diosgenin's IUPAC Standard InChIKey is WQLVFSAGQJTQCK-ICPPQKBESA-N, and its CAS Registry Number is 512-04-9. The base molecule, diosgenin, has the chemical formula C₂₇H₄₂O₃ and a molecular weight of 414.63 g/mol. It is also known under the synonyms Nitogenin and NSC 33396, and by the systematic name 3β-hydroxy-5-spirostene. The 6-keto modification alters the A/B ring junction region of this scaffold, distinguishing it from the parent aglycone.

1.2 Structural Features

Chemically, diosgenin belongs to the group of steroid sapogenins consisting of a spirostan scaffold with a characteristic spiroketal in position 22 and a hydroxy group in position 3, which is glycosylated in the corresponding saponins dioscin and protodioscin with a trisaccharide. The presence of a hydroxyl group at the 3-beta position and a double bond between carbons 5 and 6 (in base diosgenin) makes it highly reactive and structurally analogous to endogenous human steroid precursors like cholesterol and DHEA.

Its structure is characterized by a spirostan-type steroid backbone complete with hydroxyl groups. This unique tetracyclic structure is what makes diosgenin so valuable; it is the exact structural foundation required to synthesize human steroid hormones. 6-Ketodiosgenin retains this spirostan core while bearing the 6-oxo modification in place of the Δ5,6-double bond/hydroxyl arrangement of the parent compound.

When the sugar molecule (glycoside) is cleaved from the saponin, it leaves behind the aglycone, known as a sapogenin. Both diosgenin and 6-ketodiosgenin exist in this aglycone (non-glycosylated) form in dietary supplements, distinguishing them from the glycosidic saponins dioscin and protodioscin found in the intact plant.

1.3 Relationship to the Parent: Diosgenin

Diosgenin was first discovered in 1937 by Tsukamoto and colleagues in Dioscorea tokoro (Dioscoreaceae) and can be found, along with its corresponding saponins dioscin and protodioscin, in many different Dioscorea species. Diosgenin is a spiroketal steroidal natural product extracted from plants and used as the single most important precursor for the world steroid hormone industry. The Marker degradation — a series of chemical reactions developed in the mid-20th century — allowed diosgenin to serve as the starting material for the industrial production of steroid pharmaceuticals. In the mid-20th century, the discovery that diosgenin could be chemically converted into progesterone via the Marker degradation process revolutionized the pharmaceutical industry, leading to the mass production of cortisone, corticosteroids, and the first oral contraceptives.

An important pharmacological note concerns the limits of this conversion in biological contexts: the human body does not possess the laboratory conditions or the specific enzymes required to perform the Marker degradation; consuming raw diosgenin does not result in a direct conversion to testosterone or progesterone in the human bloodstream.

2. Natural Sources and Botanical Origin

2.1 Plant Sources of Diosgenin (Precursor Molecule)

Diosgenin — the direct biochemical precursor from which 6-ketodiosgenin is chemically derived — is found across a broad range of plant species. Plants including Rhizoma polygonati, Smilax china, and Trigonella foenum-graecum contain a lot of diosgenin, a steroidal sapogenin. The diosgenin-biosynthetic pathways have been characterized in Himalayan paris (Paris polyphylla), a monocot medicinal plant with hemostatic and antibacterial properties, and fenugreek (Trigonella foenum-graecum), an eudicot culinary herb commonly used as a galactagogue.

Diosgenin, a steroid sapogenin, is the product of hydrolysis by acids, strong bases, or enzymes of saponins, extracted from the tubers of Dioscorea wild yam, such as the Kokoro. The genus Dioscorea — comprising several hundred species of tropical and subtropical yams — is the industrial mainstay for diosgenin supply. Diosgenin and its analogs are widely found in the rhizomes of Dioscorea, Solanum, and other species.

The biosynthesis of diosgenin in plants proceeds via cholesterol oxidation. Both Paris polyphylla and fenugreek have independently recruited pairs of cytochromes P450 that catalyze oxidative 5,6-spiroketalization of cholesterol to produce diosgenin, with evolutionary progenitors traced to conserved phytohormone metabolism. This means the ability to synthesize diosgenin evolved independently in phylogenetically distant plant lineages, explaining its sporadic occurrences in distantly related plants.

Dioscorea zingiberensis C. H. Wright is endemic in China and widely distributed in provinces including Hubei and Shaanxi; its rhizomes are the medicinal part used in Dun-Ye-Guan-Xin-Ning tablets and for isolation of diosgenin. In India, around 100% of steroidal drugs are manufactured from Dioscorea species containing diosgenin.

2.2 Diosgenin Content in Plant Material

The main active components of dioscorea are steroidal compounds, diosgenin and its variants, which make up about 2% of the tubers. Industrial extraction typically relies on chemical hydrolysis; diosgenin is produced by different methods, but in practice, only acidic hydrolysis (with HCl and H₂SO₄) is followed due to its viability and ease, though this results in unmanageable wastewater and environmental pollution.

3. Common Forms and Preparations in Dietary Supplements

6-Ketodiosgenin is not consumed directly as a whole-food botanical preparation; it appears in the dietary supplement market as a chemically processed compound or its esterified derivatives. The NIH Dietary Supplement Label Database (DSLD) formally recognizes several distinct ingredient forms, including: 6-keto diosgenin; 6-keto-diosgenin; 6-keto diosgenin acetate; 6-keto-diosgenin acetate; 6-keto-diosgenin cypionate; 6-keto-diosgenin decanoate; 6-keto diosgenin enanthate; and 6-keto-diosgenin propionate.

The esterification strategy is borrowed from pharmaceutical steroid chemistry, with different ester chain lengths conferring different pharmacokinetic profiles. Short-chain esters are designed for rapid absorption, while long-chain esters are formulated for sustained release. Esters are attached to the base molecule to alter its fat solubility and metabolism rate; short esters (like acetate) are cleaved quickly for rapid effects, while long esters (like decanoate) are stored in lipids and release slowly over time. These supplement products typically come in oral liquid-filled capsule (liquid-cap) formats to improve delivery of these lipophilic compounds, with the rationale that the use of liquid-cap technology in modern supplements enhances the bioavailability of these highly lipophilic esterified compounds, bypassing some of the first-pass hepatic metabolism that typically degrades raw botanical powders.

The compound also appears in combination stacking products alongside other plant-derived steroidal sapogenins and anabolic botanical ingredients.

4. Traditional and Historical Use

4.1 Traditional Chinese Medicine (TCM)

The parent genus Dioscorea has a long history in Traditional Chinese Medicine (TCM). Dioscoreae rhizoma (Chinese yam, shānyào, lit. "mountain medicine") is described in traditional Chinese medicine to tonify the Qi of lung, spleen, and kidney, and to nourish the kidney's essence. Dioscorea zingiberensis C. H. Wright (Dioscoreaceae) is used extensively in traditional Chinese medicines. Dioscorea zingiberensis, also named yellow ginger (黄姜 in Chinese), is used as Traditional Chinese Medicine (TCM) and was first recorded in the Chinese medicine monograph of "Classic of Mountains and Rivers."

Chuanshanlong, obtained from Dioscorea nipponica, is used in TCM to vitalize blood and relax tendons, promote fluid metabolism, and disperse phlegm. It is mainly used in cases of arthralgia affecting the lower back and legs, and has relatively large amounts of diosgenin and related saponins, used in high doses of 15–30 grams. These species share in common the treatment of phlegm accumulation and wind-damp syndromes (arthritis and skin inflammation), which represent manifestations of turbidity and moisture accumulation — conditions generally treated by Dioscorea species.

4.2 Ayurveda and Indian Traditional Medicine

Dioscorea species are integral to various traditional medicine systems, including Ayurveda, Traditional Chinese Medicine, and African herbal medicine, for their therapeutic effects. In the Ayurvedic tradition, Dioscorea species have been employed for their nourishing, digestive, and anti-inflammatory properties; Dioscorea has been used for centuries in traditional medicine for its therapeutic benefits, such as anti-inflammatory, diuretic, and antispasmodic effects.

Dioscorea bulbifera L. (Dioscoreaceae) is extensively used in African, Chinese, and Indian traditional medicinal systems and is an ingredient in many herbal and Ayurvedic preparations used against various ailments. Various researchers have reported the therapeutic potential of D. bulbifera in anthelmintic, anti-insecticidal, aphrodisiac, diuretic properties, and for curing piles, syphilis, dysentery, ulcers, inflammation, diabetes, gonorrhea, leprosy, and rheumatic arthritis.

4.3 Important Distinctions

The compound as used in modern dietary supplements — 6-ketodiosgenin, particularly its synthetic ester derivatives — is a chemically modified form with no exact analog in traditional herbal medicine. Traditional cultures used whole preparations of Dioscorea rhizome or extracts thereof, not isolated or derivatized aglycones. The pharmacology of diosgenin and the other steroidal compounds from dioscorea had not been investigated to a great extent historically; moreover, the hormonal activity of the natural compounds is quite weak. The introduction of esterified 6-ketodiosgenin as a stand-alone supplement ingredient is a modern commercial development that postdates traditional botanical use.

5. Key Constituents and Active Compounds

5.1 The Spirostan Sapogenin Class

6-Ketodiosgenin belongs to the steroidal sapogenin class, a subgroup of the broader saponin family of plant phytochemicals. In the botanical world, saponins are phytochemicals known for their soap-like foaming characteristics and potent biological activities. The spirostan scaffold of diosgenin and its 6-keto derivative is shared with many pharmacologically active steroids; diosgenin and its analogs have gained importance for their efficacy against life-threatening diseases, including cardiovascular, endocrine, nervous system diseases, and cancer.

Related steroidal sapogenins found alongside diosgenin in plant sources, including dioscin and protodioscin, provide a chemical context for understanding the compound's profile. The saponin protodioscin is additionally glycosylated in position 26, resulting in the formation of a hemiketal.

5.2 Anabolic Activity: The 6-Keto Modification

The defining pharmacological rationale for 6-ketodiosgenin as a dietary supplement derives from Soviet-era experimental research. A 1976 study by Syrov and Kurmukov, published in Farmakologiia i Toksikologiia (PMID: 1028596), remains the foundational reference for anabolic claims about this compound class. It is shown that 6-ketoderivatives of natural sapogenins, viz. agigenin, diosgenin, and alliogenin, display anabolic activity and do not manifest any androgenic properties. Specifically, the compound (25R)-5α-spirostan-2α,3β,5α-triol-6-one produces an accelerated gain of weight in rats, and also an increase in the weight of the liver, heart, kidneys, musculus tibialis anterior and augments the total amount of protein therein; all of the above-mentioned changes become more pronounced with the study substance introduced to young animals; castration of sexually immature rats greatly mitigates the anabolic effect of the compound.

This study was conducted in rodents and published over four decades ago. No human clinical trials directly investigating 6-ketodiosgenin's anabolic effects in humans have been identified in the peer-reviewed literature indexed by PubMed or PMC.

6. Mechanisms of Action

6.1 Receptor Interactions

Diosgenin (the parent of 6-ketodiosgenin) has been identified as a ligand for nuclear hormone receptors. Mice that express a truncated and dysfunctional mutant of RORα ("staggerer" mice) were shown to be resistant to diet-induced obesity, show impaired gluconeogenesis in the liver, and exhibit increased insulin sensitivity and glucose uptake in skeletal muscles; notably, many target genes, such as glucose-6-phosphatase (G6PC), were shown to be mutually regulated by RORγ and RORα. This underpins the relevance of ROR receptor modulation by diosgenin-class molecules to metabolic outcomes.

Diosgenin exhibits anticancer, cardiovascular protective, anti-diabetes, neuroprotective, immunomodulatory, estrogenic, and skin protective effects, mainly by inducing apoptosis, suppressing malignant transformation, decreasing oxidative stress, preventing inflammatory events, promoting cellular differentiation/proliferation, and regulating T-cell immune response. The estrogenic activity has been directly referenced in chemical supplier documentation: diosgenin is a steroid sapogenin with estrogenic activity.

6.2 Anti-Inflammatory Pathways

The anti-inflammatory activity of diosgenin is through inhibiting production of pro-inflammatory cytokines, enzymes, and adhesion molecules. More specifically, research has elaborated on glucocorticoid receptor-mediated pathways: diosgenin significantly reduces the secretion of different inflammatory factors including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 via upregulation of glucocorticoid receptors, secretory leukocyte protease inhibitor, glucocorticoid-induced leucine zipper, mitogen-activated protein kinases (MAPK) phosphatase 1, and downregulation of heat shock proteins (HSP70).

Additionally, the in vivo study of diosgenin compound and its impact on Wistar rats treated with an atherogenic diet showed that an atherogenic diet triggered the inflammatory mediators in the heart, liver, and brain via upregulation of COX-2, TNF-α, and NFκBp65 levels, while diosgenin treatment downregulated the level of these inflammatory markers.

6.3 Cholesterol and Lipid Metabolism

Diosgenin treatment significantly enhanced the expression of ATP-binding cassette transporter A1 (ABCA1) protein without any effect on liver X receptor α levels; additionally, diosgenin treatment also inhibits aortic atherosclerosis progression via downregulation of miR-19b proteins in THP-1 macrophages/MPM-derived foam cells. The antiatherogenic effects of diosgenin can be explained not only by a reduction in intestinal cholesterol absorption but also via suppression of the miR-19b-induced downregulation of ATP-binding cassette transporter A1 in macrophages.

6.4 Neuroprotective Mechanisms

The signal pathway of diosgenin is initiated by activation of 1,25D₃-membrane-associated rapid response steroid-binding receptor (MARRS), and reduction in heat shock cognate 70 in neurons. Diosgenin administration promotes the extension of long axons from the hippocampus to the prefrontal cortex in mouse models of Alzheimer's disease. Research also identified a key molecular mediator: secreted protein acidic and rich in cysteine (SPARC) was the most expressed gene in axon-growing neurons; neuron-specific overexpression of SPARC via adeno-associated virus serotype 9 delivery in the hippocampus recovered memory deficits and axonal projection to the prefrontal cortex in 5XFAD mice.

6.5 Cancer Cell Pathways

Diosgenin interferes with cell death pathways and their regulators to induce apoptosis; it antagonizes tumor metastasis by modulating epithelial-mesenchymal transition and actin cytoskeleton to change cellular motility, suppressing degradation of matrix barrier, and inhibiting angiogenesis. Additionally, diosgenin improves antioxidant status and inhibits lipid peroxidation.

6.6 Membrane and Cellular Effects

Diosgenin has a positive effect on endothelial dysfunction associated with insulin resistance by means of an IKKβ/IRS-1-dependent manner, and therefore can be useful in the prevention or treatment of cardiovascular disorders involved in insulin resistance and diabetes. Chronic administration of diosgenin to diabetic rats has a hypoglycemic effect and could restore vascular reactivity via endothelium-dependent and independent mechanisms and at least partially by offsetting lipid peroxidation, apoptosis, and inflammation.

7. Scientific Evidence by Area of Use

7.1 Anabolic / Skeletal Muscle Effects

Evidence type: Primarily animal (rodent) experimental; no identified human clinical trials for 6-ketodiosgenin specifically.

The primary scientific claim for 6-ketodiosgenin in sports nutrition is anabolic activity without androgenic effects. The foundational study by Syrov and Kurmukov (1976) demonstrated anabolic effects of 6-keto sapogenin derivatives in rats, showing weight gain and increased tissue protein. It was shown that 6-ketoderivatives of natural sapogenins, viz. agigenin, diosgenin, and alliogenin, display anabolic activity and do not manifest any androgenic properties. However, this is a single, decades-old animal study and no direct human clinical trial data on 6-ketodiosgenin's anabolic efficacy has been located in the peer-reviewed literature.

For the parent compound diosgenin, one study in rodents found beneficial muscle effects. There is not much clinical research directly supporting 6-Keto Diosgenin's effectiveness in humans; most of the evidence comes from anecdotal reports and some preliminary studies involving animals; human trials are still lacking.

7.2 Cardiovascular and Lipid Health

Evidence type: Preclinical (in vitro and animal); limited clinical data, largely pertaining to diosgenin-containing traditional medicines rather than isolated 6-ketodiosgenin.

Recent data suggest diosgenin plays an anti-atherosclerosis role through its anti-inflammatory, antioxidant, plasma cholesterol-lowering, anti-proliferation, and anti-thrombotic effects. Diosgenin and its analogs are important natural steroidal saponins used as active ingredients of dioscin tablets, Di'ao Xin Xue Kang capsules, Dunye Guan Xin Ning, and other medicines which have been used in China for more than 20 years to treat coronary heart disease and other cardiovascular diseases; many experimental studies and some clinical trials have demonstrated that diosgenin and its analogs have anti-inflammatory, antioxidant, plasma cholesterol-lowering, anti-proliferation, and anti-thrombotic effects.

Numerous studies have shown that diosgenin has potential therapeutic value for lipid metabolism diseases via various pathways and mechanisms, such as controlling lipid synthesis, absorption, and inhibition of oxidative stress. Research focuses on data from animal and clinical studies summarizing the pharmacological mechanism of diosgenin in treatment of lipid metabolism disorders, especially in obesity, hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, and diabetes. The clinical evidence, however, involves diosgenin-containing plant preparations rather than isolated 6-ketodiosgenin.

7.3 Oncology and Anti-Cancer Properties

Evidence type: Preclinical only (in vitro and animal models); no human oncology trials identified for 6-ketodiosgenin or diosgenin.

In addition to being a lactation aid, diosgenin has been shown to be hypocholesterolemic, gastro- and hepato-protective, anti-oxidant, anti-inflammatory, anti-diabetic, and anti-cancer. Diosgenin has a unique structural similarity to estrogen; several preclinical studies have reported on the pro-apoptotic and anti-cancer properties of diosgenin against a variety of cancers, both in vitro and in vivo; diosgenin has also been reported to reverse multi-drug resistance in cancer cells and sensitize cancer cells to standard chemotherapy.

It is well known that the majority of cancers are a consequence of chronic inflammation, infection, dysfunctional cell death mechanisms, and deregulation of cell cycle molecules; the ability of diosgenin to prevent carcinogenesis by acting as an anti-oxidant and anti-inflammatory agent, and its ability to induce apoptosis of cancer cells, suggests that it can be useful as an anti-carcinogenic agent. All currently available evidence on anti-cancer mechanisms is preclinical; no clinical trials in cancer patients have been identified.

7.4 Neurological and Cognitive Function

Evidence type: Preclinical animal data and one small randomized controlled trial (diosgenin-rich yam extract in healthy volunteers).

Research into diosgenin's effects on cognition and neuroprotection is among the more clinically developed areas. In preclinical models: diosgenin promoted axonal growth and regeneration in normal and Aβ-treated cultured neurons, and induced memory enhancement in normal mice, 5XFAD mice, and healthy humans; importantly, diosgenin administration reduces abnormally swollen axons in 5XFAD mouse brains; diosgenin also increases cross-correlational spike firing between the hippocampal CA1 and the prefrontal cortex in normal mice.

One human clinical trial has been published: a placebo-controlled, randomized, double-blind, cross-over study was performed on 28 healthy volunteers (age 20–81 years) randomly treated with yam extract or placebo (12-weeks intake and 6-week washout period); the Japanese version of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test was evaluated; diosgenin-rich yam extract consumption (12 weeks) significantly increased synaptic fluency or enhanced cognitive function without any side effects.

This single small study (n=28) used a diosgenin-rich yam extract, not isolated 6-ketodiosgenin. The trial is underpowered to draw firm conclusions and has not been replicated at scale. Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies; clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause.

7.5 Metabolic Effects: Diabetes and Obesity

Evidence type: Primarily animal model data; some clinical context from traditional medicine use.

Diosgenin represents a promising bioactive biomolecule that exhibits various biological properties including hypolipidemic, hypoglycemic, antioxidant, anti-inflammatory, and antiproliferative activities. The adipogenic activity of diosgenin is influenced by PPARγ and PPARα. Animal research has explored effects on the diabetic vasculature, showing that diosgenin can restore vascular function in diabetic animal models. No clinical trials specifically examining 6-ketodiosgenin in diabetes or obesity management have been identified.

7.6 Bone Health and Menopause

Evidence type: Preclinical animal data; one small human study (cognitive/menopause outcomes, not bone density) using diosgenin-rich extract.

Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, and bone health. Diosgenin's structural similarity to estrogen underpins its investigation in postmenopausal settings, though rigorous clinical evidence remains limited. The plant-based preparations used in some traditional medicines (e.g., Dun-Ye-Guan-Xin-Ning) have been used in China for decades in cardiovascular and potentially menopausal contexts, but these are multi-compound preparations and cannot be attributed to 6-ketodiosgenin alone.

7.7 Inflammation and Arthritis

Evidence type: In vitro and animal models; limited clinical data specifically for 6-ketodiosgenin.

Diosgenin, a spirostanol glycoside, is being investigated as a potential treatment for rheumatoid arthritis, though in amounts much larger than would be obtained from shanyao in traditional preparations. The anti-inflammatory activity of diosgenin is a known relevant effect of this steroid and has relevant interest in a variety of pathologies; however, its mechanism of action is still unclear.

8. Body Systems and Health Areas Associated with 6-Ketodiosgenin and Diosgenin

• Musculoskeletal system: Anabolic activity in animal models (protein synthesis, muscle mass) without androgenic effects; historical use for arthralgia in TCM.
• Cardiovascular system: Diosgenin plays an anti-atherosclerosis role through its anti-inflammatory, antioxidant, plasma cholesterol-lowering, anti-proliferation, and anti-thrombotic effects.
• Central nervous system: Axonal growth promotion, cognitive function enhancement, neuroprotection against Alzheimer-related pathology — studied via the MARRS receptor pathway.
• Endocrine system: Estrogenic and potentially androgenic-adjacent activity via structural similarity to steroid hormones; used as a precursor in the pharmaceutical synthesis of corticosteroids and contraceptives.
• Metabolic system: Diosgenin exhibits cardiovascular protective, anti-diabetes, and immunomodulatory effects, mainly by decreasing oxidative stress and preventing inflammatory events.
• Hepatic system: Studied for gastro- and hepatoprotective effects at moderate doses; diosgenin has been shown to be gastro- and hepato-protective.
• Oncology: Preclinical pro-apoptotic and anti-proliferative effects across multiple cancer cell lines; not established in humans.

9. Dosage Forms and Reported Dosages

There are no established clinical dosage guidelines for 6-ketodiosgenin specifically, as no controlled human clinical trials of this compound have been published in indexed peer-reviewed literature.

For the broader context of diosgenin research:

• The cognitive function human trial used a diosgenin-rich yam extract administered for 12 weeks in a crossover design, followed by a 6-week washout, in 28 healthy volunteers aged 20–81 years. The specific dose of diosgenin in milligrams was not reported in the abstract data available from this search.
• In TCM, one species (Dioscorea nipponica; Chuanshanlong) is used in high doses of 15–30 grams of the raw herb for arthralgia, though these are whole-herb preparations containing many compounds alongside diosgenin.
• Preclinical toxicity studies in rats referenced doses of diosgenin above 300 mg/kg/day to produce adverse effects (see Safety section below). Human equivalent doses derived from such figures are not validated in clinical literature.

In supplement products featuring 6-ketodiosgenin and its esters, the compound appears in combination formulations; no independently verified clinical dosing data for these commercial preparations has been located in authoritative sources.

10. Safety Considerations

10.1 Preclinical Toxicology of the Diosgenin Parent

Natural steroid saponins usually have high safety. Animal toxicology data on diosgenin is broadly reassuring at conventional doses. Preclinical studies showed mild subchronic toxicity in male rats but not in female rats treated with diosgenin; daily administration of diosgenin above 300 mg/kg may cause mild gastrointestinal distension, hemolytic anemia, and weight loss in rats, while long-term use of steroidal saponins in large doses has been reported to damage the liver, leading to liver damage such as acute icteric hepatitis; however, at a moderate dose, diosgenin showed a significant protective effect on liver injury induced by ethanol and paracetamol; Tohda et al. suggested that the oral toxicity dosage (LD50) of diosgenin to mice and rats is greater than 8000 mg/kg (equivalent to greater than 480 g in a human).

Furthermore, natural steroid saponins are generally considered safe; preclinical studies showed mild subchronic toxicity in male rats but not in female rats treated with diosgenin; therefore, diosgenin and its analogs are considered safe and non-toxic at the conventional dosage, however, the safety of other analogs needs to be further explored.

10.2 Endocrine and Reproductive Toxicity Concerns

A significant body of research raises concerns about endocrine-disrupting potential at supraphysiological doses. Dietary phytoestrogens are the main source of environmental contamination due to their estrogen-mimicking and endocrine-disrupting effects; diosgenin, a phytosteroid saponin, is used in many traditional medicines, nutraceuticals, dietary supplements, contraceptives, and hormone replacement therapies against numerous diseases and disorders; it is important to be aware of the potential risks associated with diosgenin, as well as its potential to cause reproductive and endocrine toxicity.

Due to the lack of research on the safety and probable adverse side effects of diosgenin, one study evaluated the endocrine-disrupting and reproductive toxicity of diosgenin in albino mice by following acute toxicity (OECD-423), repeated dose 90-day oral toxicity (OECD-468), and F1 extended one-generation reproductive toxicity (OECD-443) studies. The conclusion of this research was that diosgenin should be used carefully in food products and medical applications due to its potential endocrine-disrupting and reproductive toxic effects.

10.3 Safety Profile of 6-Ketodiosgenin Specifically

Contrary to the therapeutic potential of diosgenin, there is no report available on its safety, toxicity, and possible side effects in terms of dose and duration for 6-ketodiosgenin specifically. This represents a significant evidence gap: the ester derivatives of 6-ketodiosgenin (acetate, propionate, cypionate, decanoate, enanthate) found in dietary supplements have not been formally evaluated in published human safety studies in peer-reviewed literature indexed by PubMed or PMC.

In vitro cytotoxicity data show differential tissue effects: diosgenin and its derivatives were more toxic in V79 fibroblasts (IC50 40–300 µM) than in hepatocytes (IC50 280–1000 µM); inhibition of cytochrome P450IIIA in cultured hepatocytes by incubation with cimetidine did not alter the toxicity of these compounds in these cells.

10.4 Structural Non-Equivalence to Androgens

The supplement industry has emphasized that 6-ketodiosgenin is not an androgen receptor agonist. The founding 1976 animal research confirms that 6-ketoderivatives of natural sapogenins, viz. agigenin, diosgenin, and alliogenin, display the anabolic activity and do not manifest any androgenic properties. This lack of androgenic activity has been interpreted to mean the compound does not act like anabolic-androgenic steroids, though this conclusion is drawn entirely from animal research and has not been confirmed in human pharmacological studies.

10.5 Pharmaceutical Synthesis Background

The sugar-free (aglycone) diosgenin is used for the commercial synthesis of cortisone, pregnenolone, progesterone, and other steroid products. This industrial use, while scientifically significant, pertains to semi-synthesis under controlled laboratory conditions and is not applicable to the metabolism of ingested diosgenin or 6-ketodiosgenin in human consumers.

10.6 Status in NIH Dietary Supplement Label Database

The NIH's Dietary Supplement Label Database (DSLD) is a searchable database of current and historical label information from products marketed in the U.S. 6-Keto Diosgenin and its ester variants (acetate, propionate, cypionate, decanoate, enanthate) all appear as registered ingredients in the DSLD, confirming commercial market presence. However, the manufacturer or distributor is responsible for label information; the labels might be incomplete and/or inaccurate and the products might contain ingredients of concern to the FDA; the FDA maintains lists of ingredients of concern and products that are adulterated or misbranded; the inclusion of a product and its label in the DSLD is not an endorsement of that product or a guarantee of accuracy by the Office of Dietary Supplements, NIH, FDA, nor U.S. Department of Health and Human Services.

11. Overall Evidence Assessment

6-Ketodiosgenin as a distinct supplement ingredient occupies an unusual position: it is rooted in a well-characterized natural compound (diosgenin) with a substantial preclinical literature, yet it has itself been the subject of only a single identified peer-reviewed experimental study (the 1976 Syrov and Kurmukov animal study). The parent molecule diosgenin has a considerably broader research base, including one small human RCT for cognitive outcomes and a body of animal and in vitro research across cardiovascular, oncological, neurological, and metabolic domains. However, the majority of this preclinical evidence cannot be straightforwardly extrapolated to 6-ketodiosgenin or its ester derivatives, as structural modifications alter binding affinities, metabolism, and bioavailability. There is not much clinical research directly supporting 6-Keto Diosgenin's effectiveness in humans; most of the evidence comes from anecdotal reports and some preliminary studies involving animals; human trials are still lacking.

The esterified derivative forms commercially marketed (acetate, propionate, cypionate, decanoate, enanthate) have no specific published human clinical safety or efficacy data in indexed literature as of the date of this writing. All claims about these variants' superior bioavailability or sustained release relative to unmodified 6-ketodiosgenin are, at this time, unsupported by published human pharmacokinetic data.

References

• Syrov VN, Kurmukov AG. Experimental study of the anabolic activity of 6-ketoderivatives of certain natural sapogenins. Farmakologiia i Toksikologiia. 1976;39(5):631–635. PubMed PMID: 1028596
• Habtemariam S, et al. Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. PMC / Biomedicines. 2022.
• Jesus M, et al. An update on the biological and pharmacological activities of diosgenin. PMC / Natural Product Communications. 2017.
• Pereira A, et al. Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology. PMC. 2017.
• Chen Y, et al. Advances in the pharmacological activities and mechanisms of diosgenin. Chinese Journal of Natural Medicines. 2015;13(8):578–587. PubMed PMID: 26253490
• Raju J, Mehta R. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients. 2018;10(5):645. PubMed PMID: 29783752
• Wang T, et al. Therapeutic potential and research progress of diosgenin for lipid metabolism diseases. PubMed. 2022.
• Wang X, et al. Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis. Drug Design, Development and Therapy. PMC. 2022.
• Kuboyama T, et al. Diosgenin restores memory function via SPARC-driven axonal growth from the hippocampus to the PFC in Alzheimer's disease model mice. Molecular Psychiatry. PMC. 2023.
• Klingelhoefer S, et al. Identification of the Natural Steroid Sapogenin Diosgenin as a Direct Dual-Specific RORα/γ Inverse Agonist. Biomedicines. PMC. 2022.
• Miettinen K, et al. Repeated evolution of cytochrome P450-mediated spiroketal steroid biosynthesis in plants. Nature Communications. PMC. 2019.
• Rashed MH, et al. Enhanced Neuroprotection by Diosgenin and Pterostilbene Combination Against Neurotoxicity Induced by Amyloid-Β 1-42 in SH-SY5Y Differentiated Cell Models. PMC. 2025.
• Naz S, et al. Dietary phytoestrogen diosgenin interrupts metabolism, physiology, and reproduction of Swiss albino mice. Food and Chemical Toxicology. 2023.
• Zhang Y, et al. Research progress of diosgenin extraction from Dioscorea zingiberensis C. H. Wright. Steroids. 2023.
• Huang L, et al. Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity. Journal of Ethnopharmacology. 2018.
• Wang X, et al. Diosgenin and its Analogs: Potential Protective Agents Against Atherosclerosis. Dove Medical Press / Drug Design, Development and Therapy. 2022.
• NIH Office of Dietary Supplements. Dietary Supplement Label Database (DSLD): 6-Keto Diosgenin Acetate (Ingredient).
• NIH Office of Dietary Supplements. Dietary Supplement Label Database (DSLD): 6-Keto Diosgenin (Ingredient).
• Institute for Traditional Medicine. Dioscorea Used in Chinese Medicine with the Example of Qianjin Zhidai Wan.
• NIST WebBook: Diosgenin (CAS 512-04-9). National Institute of Standards and Technology.
• Semantic Scholar entry: Syrov VN, Kurmukov AG. Experimental study of the anabolic activity of 6-ketoderivatives of certain natural sapogenins. 1976.